Codi QR

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differ...

Descripció completa

Guardat en:
Autors principals: Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021-03-01
Col·lecció:Frontiers in Oncology
Matèries:
acute myeloid leukemia
AML
enasidenib
IDH
isocitrate dehydrogenase
ivosidenib
Accés en línia:https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars